Clinical Trial

A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)

Name: A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK) — clinical trial record (NCT07401875)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

To find out if the combination of HC-7366 and nivolumab (with or without ipilimumab) can help to control ccRCC. The

Protocol Amendment History 1 change

critical Recruitment opened 2026-04-03

Trial Details

NCT Number	NCT07401875
Lead Sponsor	M.D. Anderson Cancer Center Collaborators: HiberCell, Inc.
Conditions	Phase 1b, HC-7366, SHARK, Kidney Cancer
Enrollment	35 participants
Start Date	2026-03-24
Primary Completion	2027-11-30 (estimated)
Study Completion	2029-11-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-02